Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 10, 2004, Pages 534-542

  van Troostenburg, A R ^a   Clark, E V ^a   Carey, W D H ^a   Warrington, S J ^a   Kerns, W D ^b   Cohn, I ^b   Silverman, M H ^b   Bar Yehuda, S ^b   Fong, K L L ^c   Fishman, P ^b  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b Can Fite BioPharma Ltd   (Israel)

^c Calvert Laboratories Inc   (United States)

Author keywords

A3 adenosine receptor agonist; CF101; Healthy volunteers; Hemodynamics; Pharmacokinetics; Tolerance

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR AGONIST; CREMOPHOR; DRUG VEHICLE; METHYL 1 [N6 (3 IODOBENZYL)ADENIN 9 YL] BETA DEXTRO IBOFURONAMIDE; METHYLCELLULOSE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BONE PAIN; CLINICAL STUDY; CLINICAL TRIAL; COMMON COLD; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FACE DISORDER; FATIGUE; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HEMODYNAMICS; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW BACK PAIN; MALE; MOUTH ULCER; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA AND VOMITING; NEUTROPHIL; NORMAL HUMAN; PARALLEL DESIGN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SUSPENSION; SYNCOPE; TACHYCARDIA; THORAX PAIN; VOLUNTEER;

EID: 6344278503     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp42534     Document Type: Article

References (13)

1. Bar-Yehuda S, Barer F, Volfsson L, Fishman P 2001 Resistance of muscle to tumor metastases: a role for A3 adenosine receptor agonists. Neoplasia 3: 1-7
2. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, Fishman P 2002 Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 30: 1390-1398
3. Fishman P, Bar-Yehuda S, Ohana G, PathakS, Wasserman L, Barer F, Multani A 2000 Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer 36: 1452-1458
4. Fishman P, Bar-Yehuda S, Rath-Wolfson L, Ardon E, Barrer F, Ochaion A, Madi L 2003 Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonists. Anticancer Res in press
5. Fishman P, Bar-Yehuda S, Farberstein T, Barer F, Ohana G 2000 Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol 183: 393-398
6. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K 2002 Evidence for involvement of Wnt signalling pathway in IB-MECA-mediated suppression of melanoma cells. Oncogene 21: 4060-4064
7. Lasley R, Narayan P, Jahania S et al 1999 Species-dependent hemodynamic effects of adenosine A3 receptor agonists IB-MECA and Cl-IB-MECA. Am J Physiol 276: H2076-H2084
8. Linden B 1994 Cloned adenosine A3 receptors: pharmacological properties, species differences, and receptor function. TiPS 15: 298-306
9. Merighi S, Varami K, Fessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, Borea P 2001 Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134: 1215-1226
10. Pollard Y, Watts MJ, Grant D et al 1999 Use of the hemopoietic progenitor cell count of the Sysmex SE-9500 to refine apheresis timing of peripheral blood stem cells. Br J Haematol 106: 538-544
11. Poulsen S, Quinn R 1998 Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 6: 619-41
12. Watts MJ, Jones HM, Sullivan AM et al 1995 Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid hematological recovery following peripheral blood stem cell transplantation. Br J Haematol 91: 767-72
13. Watts MJ, Addison I, Long SG et al 1997 Crossover study of the hematological effects and pharmacokinetics of glycosylated and nonglycosylated G-CSF in healthy volunteers. Br J Haematol 98: 474-479